Schizoaffective Disorder, Schizophrenia
Conditions
Keywords
Schizophrenia, Schizoaffective disorder, Aripiprazole
Brief summary
The purpose of this study is to prove safety and efficacy of aripiprazole.
Detailed description
This study was designed to prove safety and efficacy of aripiprazole in the treatment of acutely relapsed patients with diagnoses of schizophrenia or schizoaffective disorder in Korea and to confirm the maintenance of efficacy and safety during maintenance period and the changes in emotional factors and social functions. After administering 15 mg/day of aripiprazole for two weeks, the test may change the dose within the range of 10 mg and 30 mg per day by clinical judgment. (Medication duration: 8 weeks (acute phase) + 18 weeks (maintenance phase)\] + 26 weeks (extension phase), \*total 52 weeks)
Interventions
DRUGAripiprazole
Sponsors
Korea Otsuka Pharmaceutical Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Schizophrenia or schizoaffective disorder patients as defined by the DSM-IV criteria having an acute relapse 2. 18 to 65 years 3. Males and females (females of child bearing potential must use acceptable contraception and must not be pregnant and lactating; females of child-bearing potential must have negative serum pregnancy test) 4. Randomization to this study must occur no more than four weeks following the day of initiation of treatment for the present episode/relapse. 5. Should have a total PANSS score of at least 60. In addition, patients should have scores of at least 4 (moderate) on any two of the four PANSS items that constitute the psychotic item subscale (hallucinatory behavior, delusions, conceptual disorganization, and suspiciousness). 6. Patients must be able to be rated reliably on the battery of psychiatric and movement rating scales required by the protocol. 7. Patients eligible to enter the study must sign an informed consent form.
Exclusion criteria
1. Patients who are violent 2. Patients who, in the opinion of the investigator, have serious suicidal ideation 3. Patients who are liable to serious suicide attempt, by clinical judgment 4. Patients who currently have a psychiatric diagnosis other than schizophrenia, schizophrenic form disorder or schizoaffective disorder requiring pharmacotherapy 5. Patients who have any of the following neurologic diagnoses: migraine, epilepsy, Parkinson's disease, Alzheimer's disease, multiple sclerosis, residual of stroke, transient cerebral ischemic attacks, cerebral palsy or any other condition that requires intermittent or maintenance treatment, or which is manifested by any abnormality on neurologic examination 6. Patients who must continue to take, or who may potentially need to take, during this study, any of the following concomitant medication, which could cause unwanted drug-to-drug interactions or which could confound the analysis of antipsychotic effectiveness: Tegretol (carbamazepine), Depakene Depakote (valproic acid or sodium valproate or divalproate sodium), Lithium carbonate and lithium citrate 7. Patients under treatment of schizophrenia : those who had taken antipsychotic drugs (consta) before randomization 8. Patients who must continue to take, during this study, drugs or substances known as strong suppressive agents of microsomal enzyme CYP2D6 9. Patients with any gastrointestinal resection, stomach stapling, or any other condition that may impair the absorption of the study medication 10. Patients who currently meet the DSM-IV criteria for psychoactive substance dependence or patients with a history of substance or alcohol dependence (according to the DSM-IV criteria) within one month prior to the beginning of the study 11. Patients having any somatic condition whose symptoms or physical signs could be misinterpreted as signs or symptoms of psychosis or as adverse effects from antipsychotic medications. 12. Patients with any acute or unstable medical condition requiring pharmacotherapy 13. Patients with any abnormal laboratory test result as judged by investigator 14. Patients who have participated in any previous aripiprazole clinical study 15. Patients having taken an investigational drug within the four weeks which precede the start of placebo washout
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PANSS-total score (at screening, week 1, 2, 3, 4, 6, 8, 12, 16, 26, 40, 52) | — |
Secondary
| Measure | Time frame |
|---|---|
| [Safety] AEs (at baseline, week 1, 2, 3, 4, 6, 8, 12, 16, 26, 40, 52) | — |
| SAS, AIMS, Barnes (at baseline, week 1, 2, 3, 4, 6, 8, 12, 16, 26, 40, 52) | — |
| vital signs (at screening, baseline, week 1, 2, 3, 4, 6, 8, 12, 16, 26, 40, 52) | — |
| body weight (at screening, baseline, week 1, 2, 3, 4, 6, 8, 12, 16, 26, 40, 52) | — |
| [Efficacy] PANSS-positive, PANSS-negative, CGI-severity score (at screening, week 1, 2, 3, 4, 6, 8, 12, 16, 26, 40, 52) | — |
| serum prolactin concentration (at screening & week 8) | — |
| routine laboratory test (at screening & week 8) | — |
| urinalysis (at screening & week 8) | — |
| Pharmacokinetic is evaluated by concentration of aripiprazole in blood (at Week 3, 4, 6, 8). | — |
| electrocardiogram (ECG) (at screening & week 8) | — |
Countries
South Korea
Outcome results
None listed